 SOUTH SAN FRANCISCO, Calif., June 21, 2022 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB, a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus HBV and other viral diseases, plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-α receptor IFNAR agonist designed to selectively activate the interferon-α pathway within the liver and offer the convenience of oral dosing. 